Reuters logo
BRIEF-AstraZeneca receives FDA response to hyperkalaemia drug application
March 17, 2017 / 7:28 AM / in 7 months

BRIEF-AstraZeneca receives FDA response to hyperkalaemia drug application

March 17 (Reuters) - Astrazeneca Plc

* Receives complete response letter from US FDA for zs-9 (sodium zirconium cyclosilicate) for hyperkalaemia

* Crl does not require generation of any new clinical data

* Astrazeneca and ZS Pharma are committed to working with fda to resolve remaining matters under review as soon as possible Source text for Eikon: Further company coverage: (London newsroom)

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below